Eli Lilly and Company logo
Eli Lilly and Company (LLY)
Compare

LLY Cash Flow Statement

Operating, investing, and financing cash flow analysis

LLY Quarterly Cash Flow Statement (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
Cash from Operations (CFO)
20.480B5.333B3.225B8.836B3.087B1.666B2.474B3.712B1.466B
25.275B7.396B6.636B5.582B5.660B2.759B4.410B970.300M2.967B
Depreciation & Amortization
1.610B509.000M152.200M470.000M478.500M462.800M484.800M466.800M414.400M
633.300M161.000M136.100M151.100M185.100M153.700M141.900M133.200M211.100M
Change in Accounts Receivable
69.215B21.177B17.760B16.107B14.170B12.037B11.006B10.295B11.028B
Change in Inventory
Change in Accounts Payable
Change in Working Capital
-6.393B-1.664B-3.674B1.208B-2.263B-3.364B-2.225B-9.800M-1.399B
Cash from Investing
-6.901B-2.326B-2.547B-223.900M-1.804B-3.267B-1.747B-4.171B-1.403B
-1.719B-1.058B-111.600M-549.400M0.000.000.000.00-947.700M
Cash from Financing
Debt Repayment
-5.264B-2.356B-1.508B-708.100M-692.200M-1.200B-2.054B-446.100M0.00
-5.586B-1.548B-1.345B-1.345B-1.347B-1.346B-1.168B-1.171B-1.172B
13.580B3.007B677.900M8.612B1.283B-1.601B726.600M-458.900M63.400M
Net Change in Cash
2.189B-1.986B-2.524B6.416B282.600M-175.100M-100.600M145.400M763.400M

LLY Annual Cash Flow Statement (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Cash from Operations (CFO)
16.813B8.818B4.240B7.586B7.366B6.500B4.837B5.524B
20.638B10.590B5.240B6.245B5.582B6.194B8.318B3.232B
Depreciation & Amortization
1.563B1.767B1.527B1.522B1.548B1.324B1.233B1.609B
626.000M645.600M628.500M371.100M342.800M308.100M312.400M279.500M
Change in Accounts Receivable
17.760B11.006B9.091B6.896B6.673B5.875B4.547B4.594B
Change in Inventory
Change in Accounts Payable
Change in Working Capital
-8.093B-5.385B-3.055B-800K-1.013B-747.400M-1.687B-2.379B
Cash from Investing
-7.841B-8.404B-7.392B-2.985B-1.978B-2.029B-1.353B-3.018B
-661.000M-947.700M-1.044B-327.200M-747.400M-849.300M-6.937B0.00
Cash from Financing
Debt Repayment
-4.108B-2.500B-750.000M-1.500B-1.250B-500.000M-4.400B-4.151B
-5.384B-4.680B-4.069B-3.536B-3.087B-2.687B-2.410B-2.312B
8.972B414.300M-3.152B4.600B5.388B4.471B3.483B2.506B
Net Change in Cash
4.000B449.800M751.600M-1.752B161.400M1.320B-5.661B1.462B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Indianapolis, IN
47,000 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
David A. Ricks